Carl Schoellhammer: viability is the crucial third pillar in CGT

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/8e/18/68/8e1868dc-f19d-0a3b-5c97-f0aceede2b43/mza_15123957094614483735.jpg/600x600bb.jpg

Ori Spotlight

Ori Biotech

49 episodes

6 days ago

Ori Spotlight covers the latest in cell and gene therapy. Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments. Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect

Life Sciences

Science

RSS

All content for Ori Spotlight is the property of Ori Biotech and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/14589339/14589339-1719321759358-d01f7b63d0a2a.jpg

Carl Schoellhammer: viability is the crucial third pillar in CGT

Ori Spotlight

48 minutes 55 seconds

1 year ago

Carl Schoellhammer: viability is the crucial third pillar in CGT

In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs). Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles. Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/